Dulan Lokuwithana

Sanofi's (SNY) oral therapy, rilzabrutinib, shows promise in a Phase 3 trial for an autoimmune blood disorder called immune thrombocytopenia. Read more here.

Sanofi ( NASDAQ: SNY ) announced Tuesday that rilzabrutinib, an oral therapy for an autoimmune blood disorder called immune thrombocytopenia (ITP), reached the primary endpoint in a Phase 3 trial.

Video sharing site TikTok owned by ByteDance (BDNCE) is going to restrict most content related to weight loss drugs such as Novo's (NVO) Ozempic. Read more here.

Medpace Holdings ( NASDAQ: MEDP ) traded higher on Tuesday as Jefferies upgraded the stock to Buy from Hold soon after the contract research organization exceeded Street forecasts with its Q1 2024 earnings.

Medpace Holdings (MEDP) stock receives an upgrade from Jefferies as the contract research organization exceeds Q1 earnings expectations. Read more here.

The FDA approves Day One Biopharmaceuticals' (DAWN) lead asset tovorafenib for pediatric low-grade glioma, a common brain tumor in children. Read more here.

The U.S. Food and Drug Administration (FDA) on Tuesday greenlighted Day One Biopharmaceuticals' ( NASDAQ: DAWN ) lead candidate tovorafenib for a type of pediatric brain cancer called low-grade glioma.

Neurocrine Biosciences (NBIX) stock rises as its Phase 2 trial for depression therapy NBI-1065845 reached its goals. Read more here.

Neurocrine Biosciences ( NASDAQ: NBIX ) announced Tuesday that its Phase 2 SAVITRI trial for depression therapy NBI-1065845, developed in partnership

Popular social media platform TikTok is cracking down on most content related to weight loss drugs starting next month, according to the video-sharing site's new community guidelines published last week.